Get the Stockscreener App
3.97
5.92%
-0.25
After Hours:
3.96
-0.01
-0.25%
Dogwood Therapeutics Inc stock is traded at $3.97, with a volume of 20,343.
It is down -5.92% in the last 24 hours and down -33.94% over the past month.
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$4.22
Open:
$4.21
24h Volume:
20,343
Relative Volume:
0.35
Market Cap:
$118.02M
Revenue:
-
Net Income/Loss:
$-24.74M
P/E Ratio:
-0.2113
EPS:
-18.7859
Net Cash Flow:
$-15.75M
1W Performance:
-4.11%
1M Performance:
-33.94%
6M Performance:
-17.29%
1Y Performance:
+54.47%
1-Day Range:
$3.91
$4.2599
1-Week Range:
$3.91
$4.335
52-Week Range:
$1.87
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
3.97 | 125.45M | 0 | -24.74M | -15.75M | -18.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Can Dogwood Therapeutics Inc. stock rebound after recent weaknessEarnings Season Recap & Add These Before Everyone Else Does - bollywoodhelpline.com
DWTX: Positive Interim Results for Halneuron Phase 2b Trial in CINP Raising Valuation to 15 - Research Tree
Aug Chart Watch: What hedge fund activity signals for Dogwood Therapeutics Inc stockProfit Target & Stock Portfolio Risk Management - moha.gov.vn
DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15 - Zacks Small Cap Research
Trading Recap: Can Dogwood Therapeutics Inc stock hit record highs againJuly 2025 Final Week & Risk Managed Investment Entry Signals - moha.gov.vn
What date does Dogwood Therapeutics, Inc's (DWTX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Aug Big Picture: Will Dogwood Therapeutics Inc stock continue upward momentumTrade Risk Assessment & Safe Entry Point Alerts - moha.gov.vn
What's Driving the Market Sentiment Around Dogwood Therapeutics Inc? - Benzinga
Halneuron Shows Pain Relief Separation In Interim Phase 2b Trial - Nasdaq
CKLIFE SCIENCES: Positive Results Obtained from Interim Analysis of Halneuron Phase 2b Study - AASTOCKS.com
DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence - Stocktwits
Dogwood Therapeutics stock plummets after Phase 2b interim results By Investing.com - Investing.com South Africa
Dogwood Therapeutics stock plummets after Phase 2b interim results - Investing.com
Dogwood Therapeutics reports positive interim phase 2b results in chemotherapy-induced neuropathic pain - marketscreener.com
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron - marketscreener.com
Dogwood reports positive interim results for pain treatment By Investing.com - Investing.com South Africa
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain - The Manila Times
Dogwood Therapeutics Announces Positive Interim Phase 2b - GlobeNewswire
Can Dogwood Therapeutics Inc. stock sustain institutional interestQuarterly Profit Report & Smart Swing Trading Alerts - ulpravda.ru
Why retail investors favor Dogwood Therapeutics Inc. stockJuly 2025 Big Picture & Safe Swing Trade Setups - Улправда
Published on: 2025-12-21 10:22:42 - moha.gov.vn
Is Dogwood Therapeutics Inc. stock a bargain at current levelsJuly 2025 Action & Weekly Setup with ROI Potential - Улправда
Why Dogwood Therapeutics Inc. stock is recommended by analystsJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - Улправда
What hedge fund activity signals for Dogwood Therapeutics Inc. stock2025 Sector Review & Smart Swing Trading Alerts - DonanımHaber
Will Dogwood Therapeutics Inc. stock continue upward momentumWeekly Trade Recap & Verified Swing Trading Watchlist - DonanımHaber
Can Dogwood Therapeutics Inc. stock hit record highs againWeekly Investment Recap & Reliable Intraday Trade Alerts - DonanımHaber
Stock Market Recap: Why Dogwood Therapeutics Inc. stock is recommended by analysts2025 Market Overview & Safe Capital Preservation Plans - Улправда
Aug Macro: Can Dogwood Therapeutics Inc. stock sustain institutional interest2025 Top Gainers & Safe Entry Trade Reports - Улправда
Dogwood Therapeutics Earnings Notes - Trefis
Can Dogwood Therapeutics Inc. stock outperform in 2025 bull market2025 Risk Factors & Low Drawdown Momentum Ideas - Newser
Why Dogwood Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Daily Technical Forecast Reports - Newser
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 - ACCESS Newswire
Dogwood Therapeutics (Nasdaq: DWTX) files synthetic Halneuron IP, eyes 2045 exclusivity - Stock Titan
Dogwood Therapeutics (DWTX) Stock Analysis Report | Financials & Insights - Benzinga
Dogwood Therapeutics Inc enters equity distribution agreement with Northland SecuritiesSEC filing - marketscreener.com
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight - GlobeNewswire Inc.
[Form 4] Dogwood Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dogwood Therapeutics: Clinical Readout Looms As A Potential Game-Changer - RTTNews
What Institutional Trends Suggest About Pearl Polymers Limiteds DirectionSupport Zone Identification & High Return Capital Strategies - earlytimes.in
What analysts say about Dogwood Therapeutics Inc stockStock Valuation Metrics & Affordable Investment Portfolio - earlytimes.in
Dogwood Therapeutics Approves Equity Plan Amid Business Merger - The Globe and Mail
Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge - MSN
Dogwood Therapeutics shareholders approve equity plan and business combination By Investing.com - Investing.com Nigeria
Dogwood Therapeutics shareholders approve equity plan and business combination - Investing.com
[8-K] Dogwood Therapeutics, Inc. Reports Material Event | DWTX SEC FilingForm 8-K - Stock Titan
DWTX: All five board proposals, including stock conversions and equity plan, were approved - TradingView
DWTX: All five board proposals, including stock conversions and an equity plan, were approved - TradingView
Is Dogwood Therapeutics Inc. stock positioned for long term growthJuly 2025 Trends & Precise Swing Trade Entry Alerts - newser.com
How sentiment analysis helps forecast Dogwood Therapeutics Inc.Buy Signal & Safe Capital Preservation Plans - newser.com
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):